InxMed Announces First Patient Dosed in Phase 2 Pivotal Study of IN10018 In Patients with Platinum-Resistant Recurrent Ovarian Cancer


Key Topics in this News Article:

News Snapshot:

NANJING, China, Sept. 8, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates to developing innovative therapies targeting drug resistance and metastasis for hard-to-treat solid tumors, today announced the dosing of the first patient in its Phase 2 pivotal study evaluating IN10018, a highly potent and selective oral inhibitor of focal adhesion kinase (FAK), in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant recurrent ovarian cancer (PROC). The Phase 2 pivotal study is a randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of IN10018 in combination with PLD in patients with PROC. A total of...